Key Takeaways
- Volume-led 90% YoY growth, margins intact: Revenue jumped on a 108% volume increase while EBITDA margins held inside the historic 15–20% band, a combination management calls a point of pride.
- Cash flow transformed the story: H1 operating cash flow swung from under ₹2 crore to ₹47 crore as working capital days halved, raw material and freight costs eased, and debtor management improved.
- Capacity expansion already proving vital: The Ambernath plant, doubled less than a year ago, hit 66% utilization; a further 21,000-ton addition starts mid-November, with a 30,000-ton order expected imminently.
- US EPA approval unlocks the American market: HealthGuard AMIC’s non-heavy-metal antimicrobial treatment can now be specified by Walmart, Target and others for Asian manufacturers who are already Fineotex customers.
- What to watch next quarter: Whether the “certain interesting orders” materialize into the promised H2 step-up, the pace of the next capacity addition toward 150,000 tons, and any concrete move on the inorganic front.
Growth Engine: Volume, Capacity & the 30,000-Ton Order
- Volume, not price, drove the quarter: Volume rose 108% YoY, lifting revenue 90% while the company navigated a “wavy” global demand environment and textile-sector turmoil.
- Capacity doubled and already filling: The Ambernath expansion completed in late 2021 took total capacity to 83,000 tons; utilization reached ~66% this quarter, and a further 21,000-ton addition starts 15 November 2022, taking capacity to 104,000 tons.
- A large order is the trigger: Management disclosed it expects a 30,000-ton order “very soon,” making the current expansion vital; with that visibility, utilization is expected to touch 70%, with a more precise update due next month-end.
- More headroom on the same site: After the 21,000-ton addition, another 50,000 tons can be added at Ambernath, taking the site to roughly 150,000 tons total; incremental capacity additions need only two quarters and carry no significant cost.
- The growth trajectory is steep and sustained: YoY growth over the last six quarters ran 60%, 81%, 84%, 115% and now 90%; management pointed to this average of ~85% as the reference for analysts’ math while declining to give a specific FY23 revenue forecast.
Tibrewala: “Going through all this thick and think kind of a scenario, our company has still been able to perform. So, I think the underlining meaning or my message to the investors will be, you can be expecting much better performance from our company from the industrial standards for sure...”
The Cash Flow Turnaround
- Working capital nearly halved: Working capital days fell from 143 to 90, and debtor receivables dropped from 116 to 71 days, a roughly 33% improvement driven by better debtor management and inventory reduction.
- Operating cash flow swung from near-zero to ₹47 crore: H1 FY23 delivered ₹47 crore versus less than ₹2 crore in H1 last year, as raw material supply chains normalized, freight costs declined, and raw material prices softened, allowing inventory to be drawn down.
- Surfactants/FMCG business helped the cash profile: New customers including Patanjali, Tata, Powersoft and Ponvandu were added; management flagged that cash flows and working capital in this segment are a “great benefit.”
- Debt-free expansion keeps the balance sheet clean: The company remains debt-free and is funding all capacity expansion through internal accruals, with no debt used for the current build-out.
Tibrewala: “This is in fact something which I am proud of our marketing team and our strategical team where we are able to grow the turnover and keeping the EBITDA margins intact and at the same time getting better cash flows.”
Margins: Stable Inside the Historic Band
- EBITDA margins held in the 15–20% range: Management expressed pride in growing turnover while keeping margins intact over 11 listed years, and expects the same band to hold longer-term after factoring in future capex, manpower costs and sales promotion.
- The moat is technical, not commoditized: Textile chemicals are solution-based performance products, not a COA-driven business where customers can easily switch suppliers; management likened the offering to a “homeopathic solution,” which supports pricing power and wallet-share growth even when the textile sector is under stress.
- Specialty means higher EBITDA, by definition: Asked to define specialty chemicals, management stated plainly that “specialty means something which has a higher EBITDA,” and that a company without great EBITDA is not a specialty chemical company.
- H2 expected to be better across the board: Management guided that H2 will be “far better than H1,” not only in Cleaning & Hygiene but broadly across the business, on EBITDA margins, cash flows and working capital.
US EPA Approval & the HealthGuard Opportunity
- HealthGuard AMIC cleared for the US market: The non-heavy-metal-based antimicrobial treatment received US Environmental Protection Agency approval, removing the regulatory barrier to American penetration.
- The pull-through mechanism is already in place: Large US retail outlets like Walmart, Target and Turner Bianca are already recommending HealthGuard products to their textile makers in Asia; those Asian manufacturers are existing Fineotex customers, so the approval is expected to expand wallet share with them.
- Already supplied to Indian textile majors: HealthGuard products are currently supplied to Trident and Welspun, demonstrating commercial traction ahead of the US market opening.
Business Mix & the FMCG Pivot
- Cleaning & Hygiene now 38% of the business: The surfactants/FMCG segment is growing rapidly, with new customer additions and “great traction”; management will continue to focus on similar chemistry and adjacent markets.
- FDA-certified plants produce a broad home-care range: Products include floor cleaners, hand-washes, sanitizers, dishwashers and toilet bowl cleaners, positioning the company across multiple cleaning and hygiene categories.
- The branded vs own-brand split was not disclosed: An analyst asked for the specific revenue mix within FMCG between branded supply and own-brand sales; management explained the two business models but did not provide the requested split.
Capital Allocation: Inorganic Discipline & Return Ratios
- Annualized ROCE of 31% and ROE of 36%: Management described these as the best returns the company has posted, underpinned by the debt-free balance sheet and improved working capital.
- Acquisitions are “in the cards” but only on strict terms: The company is open to inorganic moves but will remain disciplined with cash deployment, focusing only on businesses with matching synergy and core alignment, while keeping valuations in mind.
- No revolutionary idea, just execution: Asked what new idea would take the company to the next league, management replied it has no great revolutionary idea to share and that the policy is to do what it is good at and become the best.
Tibrewala: “I think it is not important to have a revolutionary idea but what is more important is to do what you are good at and become the best and this is our policy always.”
Risk: What Has Already Happened
- Most perceived risks have already materialized and been navigated: Management listed China supply disruptions, Covid, container shortages, crude oil price jumps, geopolitical situations and the European slowdown as risks that have already converted into reality and been sailed through.
- Textile sector turmoil was absorbed: High cotton prices, post-Covid demand fluctuations and inventory pipeline issues created a difficult environment, yet the company maintained growth and margins by increasing wallet share with existing customers through technical, solution-based products that are not easily replaceable.
- Q3 guidance was requested but not given: An analyst noted flat QoQ revenue and profit from June to September and asked for Q3 guidance; management responded with general optimism about exciting orders and great performance but provided no numerical guidance.
Tibrewala: “As such, most of the risks which we call as risks have already happened. We have sailed by that also... I think most of the risks have really converted into reality in the past. So, I think I don't have any more risks.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Capacity expansion | 21,000-ton addition starts, taking total to 104,000 tons | 15 November 2022 |
| Utilization target | Expected to touch 70% with current order visibility; precise update due | Next month-end |
| Next capacity assessment | Assess position and decide on further expansion; if started, next addition complete | Assess by January 2023; addition by July 2023 |
| Ultimate site capacity | Additional 50,000 tons can be added at Ambernath, reaching ~150,000 tons total | No date; each increment needs ~2 quarters |
| H2 performance | H2 will be “far better than H1” across the business on EBITDA, cash flows and working capital | H2 FY23 |
| Long-term EBITDA margin | 18–20% earmarked as a good longer-term band, factoring in future capex and opex | Longer-term basis |
| Turnover aspiration | Aspires to touch ₹1,000 crores in turnover “very soon” | No date; “only concern is how fast” |
| Inorganic acquisitions | Open to acquisitions matching synergy and core business; disciplined on valuations and cash deployment | Ongoing, no timeline |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Operational revenue | ₹134.3 crore, up 71% YoY |
| EBITDA | ₹25 crore, up 70% YoY |
| EBITDA margin | ~19% |
| PAT | ₹20.7 crore, up 87% YoY |
| PAT margin | 16% |
| H1 FY23 operational revenue | ₹270 crore, up 91% YoY |
| H1 FY23 EBITDA | ₹51.3 crore, up 109% YoY |
| H1 FY23 PAT | ₹41 crore, up 97% YoY |
| Annualized ROCE | 31% |
| Annualized ROE | 36% |
| H1 FY23 operating cash flow | ₹47 crore, versus less than ₹2 crore in H1 last year |
| Working capital | 90, reduced from 143 |
| Debtors/receivables | 71, reduced from 116, a ~33% improvement |
| Total capacity | 104,000 metric tons per annum, post 21,000-ton enhancement from 15 Nov 2022 |
| Capacity utilization | ~66% on 83,000 tons |
| Volume growth | 108% YoY |
| Cleaning & Hygiene revenue share | ~35% of total revenue |
| ICRA ratings | ICRA A (long-term), ICRA A1 (short-term) |
| CAPEX for 21,000-ton expansion | ₹8 crore to ₹10 crore in the current quarter |
| Long-term EBITDA margin guidance | 18% to 20% |